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a  b  s  t  r  a  c  t
Human  T-lymphotropic  virus (HTLV)  infection  is  a high  risk  factor  for  lymphoproliferative,  inﬂammatory,
and  infectious  disorders.  The  epidemiology  of HTLV-I,  II in industrialized  countries  has  been intensively
investigated,  and mandatory  screening  of blood  supplies  for  HTLV-I/II  was  implemented  in mid-1980s  in
most  developed  and  several  developing  countries,  yet  no  expanding  investigation  has  been  executed  in
China  so  far  and  also  been  considered  as  a non-endemic  region.  However,  Gessain  et al.  reported  that  theeywords:
istory
pdate
TLV infection
hina
current number  of HTLV  carriers  in the  highly  populated  China  is very  probably  much  higher. Therefore,
gaining  insight  into  the  epidemiology  of HTLV  infections  is  essential  for  avoiding  HTLV-induced  risk.  To
introduce  the history  and  renew  the  HTLV  infection  in China,  we reviewed  literatures  and  conducted  an
investigation  among  blood  donors  in  9 provinces  in China.  Concluded  from  the  historical  and  renewed
data,  the  HTLV screen  in  China  can  be divided  into  three  stages.
©  2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDHuman T-lymphotropic virus (HTLV) infection causes lym-
hoproliferative, inﬂammatory, and infectious disorders. The
pidemiology of HTLV-I/II in industrialized countries has been
ntensively investigated, and mandatory screening of blood
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supplies for HTLV-I/II was  implemented in mid-1980s in most
developed and several developing countries, yet no expanding
investigation has been executed in China so far (Zeng et al., 1984;
Chen et al., 1989; Geng et al., 1998; Cao et al., 1998; Wang et al.,
2005; Ma  et al., 2013) and also been considered as a non-endemic
region. However, Gessain et al. reported that the current number
of HTLV carriers in the highly populated China is very probably
much higher (Gessain and Cassar, 2012). Therefore, gaining insight
into the epidemiology of HTLV infections is essential for avoiding
HTLV-induced risk. To introduce the history and renew the HTLV
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
HTLV-1/-2 prevalence information collected from the referenced literatures and this study in China.
Periods Reference Year Population Investigated
regions
No. of samples Reactive cases Conﬁrmed positives Positivity rate
(%)
First ten years 1 1985 General
population and
patients
Nationwide 10,013 8 ND ND
Second ten years 3 1995–1997 Blood donors Northeastern
China
1645 1 0 0
4  1998 Blood donors Southern China 3913 12 2 0.05
Others 484 3 0 0
5  2005 Blood donors Nationwide 1,45,293 30 19 (HTLV-1) 0.01
Third  ten years 6 2008–2011 Blood donors Central China 3548 17 3 (2 HTLV-1, 1 HTLV-2) 0.09
Others 1932 7 (5 HTLV-1,2 HTLV-2) 0.36
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nfection in China, we reviewed literatures and conducted an
nvestigation among blood donors in 9 provinces in China. Con-
luded from the historical and renewed data, the HTLV screen in
hina can be divided into three ten years periods (Table 1).
The ﬁrst ten years periods about HTLV screen started in early
980s, when the migratory route has been determined to be from
apan. In 1984, the pioneer study in Beijing and other 28 provinces
n China (Zeng et al., 1984) collected 9303 samples from normal
opulation, 700 from patients with leukemia and 10 from sus-
ected ATL patients. Only 8 (0.08%) were positive, among them 3
ere Japanese living in China, 2 were from Taiwan also living in
ainland China, 2 Chinese ladies were from mainland China and
heir husbands are positive Japanese and Taiwanese individuals,
he other one was an ALT patient. These ﬁndings strongly sug-
est that the virus may  be transmitted from Japanese to Chinese,
ecause most of the HTLV antibody positive individuals came from
apan or contact with Japanese closely. In addition, the hypothe-
is that blood transfusion possibly linkages with infection of HTLV
nd development of ATLL had been mentioned in 1989 (Chen et al.,
989).
The second ten years periods for HTLV screen were undertaken
uring 1990s and early 2000s (Geng et al., 1998; Cao et al., 1998;
ang et al., 2005). In this stage, HTLV infection investigations were
rimarily performed to ﬁnd whether the HTLV infection expanded.
he data suggest that HTLV is non-endemic throughout China.
he representative investigation conducted in 13 provinces and a
otal of 145,293 sera samples were collected from volunteer blood
onors in 2005. Thirty were positive for anti-HTLV by ELISA and
nly 19 (0.05%) samples from Fujian province were conﬁrmed pos-
tive. No conﬁrmed positive samples were found in other provinces.
o be noted, positives for anti-HTLV by ELISA can be found in several
ities, but the conﬁrmed positives were restricted to a particular
egion-Fujian province, a coastal province in southeastern China.
The third ten year periods study started in late 2000s and 2010s,
nd the results showed that HTLV infection expanded to other
rovinces including Guangdong, Zhejiang, Henan and Hubei (Ma
t al., 2013) instead of limiting to Fujian province. Our investi-
ation performed from January 2012 to July 2013 in 9 provinces
ontaining 19 blood banks in China (Table 2). There were 122,468
era samples tested. The results showed, after antibody screen-
ng using HTLV(1 + 2) antibodies ELISA diagnosis kit manufactured
y Beijing Wantai Biological Pharmacy in China, 38 (0.03%) of the
LISA-positives were conﬁrmed to be HTLV-1 positive by both
estern blot (HTLV BLOT 2.4, Genelabs, Inc., Singapore) and PCR
ethod which designed to measure ampliﬁcation products from
he gag-pro-pol polyprotein gene of HTLV-I (Xie et al., 2009), while
nly one sample from Ningde was conﬁrmed to be both HTLV-1
nd HTLV-2 antibody positive by WB.  The 38 conﬁrmed positi-
es distributed in 3 provinces, including Fujian, Guangzhou and
hejiang (Fig. 1). In details, among the 38 positives, 34 live in,22,468 224 38 (37 HTLV-1, 1 HLTV-1/-2) 0.03
Fujian province, and the positive rate was 0.08% which is 2.5-fold
of average level and 0.03% higher than the study in 2005 (Wang
et al., 2005). Two positives live in Guangdong, and two in Zhejiang
province. No positives were detected in inland provinces (Henan,
Xinjiang, Jiangxi) and northern China (Liaoning and Shandong). To
be noted, 22 of the 34 positives in Fujian live in Ningde city, 10
in Putian city, 1 in Zhangzhou city and 1 in Longyan city, which
means the region with high HTLV infection rate restricted to par-
ticular smaller region(s). We  should further inquire the potential
factor(s) of higher HTLV infection rate in Fujian province, espe-
cially in Ningde and Putian cities. Both Ningde and Putian are
coastal/port cities, and neighboring with Japan which has a high
prevalence of HTLV-1, so the answer would be the interaction with
Japanese trader or ﬁshermen, as descripted in early 1980s. More-
over, after the introduction of HTLV to China, the risk of HTLV
prevalence among Chinese through blood transfusion or other
routes in particular regions cannot be ignored. To be noted, except
for the coastal cities, HTLV infection in central China, including
Henan and Hubei was found in the ﬁrst large-scale cross-sectional
study in Central China from January 2008 to December 2011 (Ma
et al., 2013). However, the prevalence rate in central China is
lower than the coastal areas, which may  be attributed to the dif-
ferent individual susceptibility or habits and customs of people
living in and away the coastal areas, which need further explor-
ing.
In this study, we  also found an inner family transmission case.
The blood donor, who  is a 41 year old female peasant, was  con-
ﬁrmed be infected by HTLV using PCR and WB.  Her parents were
also conﬁrmed to be HTLV positive, and her husband and child
were negative. This provides us a clue to ﬁnd the transmission
types within family and the potential factors which protected
her child from infection. However, this is a complicated issue
to answer. We  think the answer may  be newly infection of
the woman through a certain route. In the other hand, not all
infected mother can transfer the virus to her child as mentioned
by Hino et al. (Hino et al., 1996) that the incidence of serocon-
version in children who  were breast-fed over 12 months was
15.7%.
In summary, China is, as a whole, a low HTLV-1 endemic area
with however some regions with a higher endemic situation. Fur-
thermore, in these areas of higher HTLV-1 prevalence, as the Fujian
region, it is important to underline that no systematic strategies
are implemented to prevent HTLV infection. However, blood borne
transmission is a potential risk. In China, except for a few hospitals
and blood centers in particular regions detecting sera of patients
and blood donors, mandatory screening for HTLV has not been per-
formed nationwide and no systematic strategies are made for HTLV
prevention and control. Therefore, it is urgent to carry out fur-
ther investigations to help developing effective control strategies
toward HTLV infection in China.
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Table  2
Prevalence of anti-HTLV among blood donors from various regions of China.
Provinces Cities No. of samples Reactive cases Conﬁrmed cases
No. Rate (%) No. Rate (%)
Fujian 41,042 139 0.34 34 0.08
Xiamen 14,013 47 0.34 0 0.00
Putian 6931 26 0.38 10 0.14
Ningde 5554 41 0.74 22 0.40
Zhangzhou 8000 28 0.35 1 0.01
Longyan 6544 17 0.26 1 0.02
Guangdong 18,452 23 0.12 2 0.01
Guangzhou 9232 9 0.10 1 0.01
Shenzhen 9220 14 0.15 1 0.01
Zhejiang 22,000 14 0.06 2 0.01
Hangzhou 5000 2 0.04 0 0.00
Ningbo 4000 1 0.03 0 0.00
Zhoushan 3000 1 0.03 1 0.03
Jiaxing 3000 3 0.10 0 0.00
Taizhou 3000 5 0.17 1 0.03
Wenzhou 4000 2 0.05 0 0.00
Liaoning 9000 5 0.06 0 0.00
Henan 8800 7 0.08 0 0.00
Shandong 4196 2 0.05 ND ND
Xinjiang 1941 2 0.10 ND ND
Jiangxi 8682 10 0.12 ND ND
Shanghai 8355 2 0.02 ND ND
Total  1,22,468 224 0.18 38 0.03
Note: ND – nondetected owing to the lack of samples.
Fig. 1. The investigated Chinese provinces and regions with the location of HTLV-1 endemic foci. Note: HTLV screening has been carried in the light gray labeled provinces
and  regions; the cities where exist HTLV positives are shown in red square, and the numbers in the bracket represent the number of positives. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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